Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Status Completed

Clinical Trial Summary

This is a multi-centre, randomized, double-blind，placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 (recombinant humanized anti-immunoglobulin E(IgE) monoclonal antibody for injection) to treat asthma patients who remain not adequately controlled despite Med/high ICS plus LABA in China. Following a screening period of up to 2 weeks and run-in period of 4 weeks, randomized patients will enter a 24-week treatment period with CMAB007 or placebo. Efficacy and safety will be assessed at 4-week intervals during the treatment period.

Clinical Trial Description

Approximately 400 asthma patients with an increased serum total IgE level(60-1500 international unit(IU)/ml) and uncontrolled receiving medium to high dose inhaled corticosteroid (ICS) plus long-acting β2-agonist(LABA) will be randomised in about 43 sites in China. They will be administered CMAB007 or placebo at a ratio of 2:1 for 24 weeks. During the whole study, all subjects will be on regularly fixed combination of med/high ICS and LABA (budesonide and formoterol fumarate powder for inhalation or salmeterol xinafoate and fluticasone propionate powder for inhalation). They should complete PEF measurement and patient diary daily and be assessed every 4 weeks. Spirometry, questionnaires, laboratory tests and so on will be performed. At selected sites, about 45 patients will be enrolled in a sub-study to assess the pharmacokinetic and pharmacodynamic characterises of CMAB007. Anti-drug antibody (ADA) will be sampled at V1, V2 and V7 too. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03468790
Study type	Interventional
Source	Shanghai Biomabs Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 3
Start date	May 9, 2018
Completion date	March 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04435990` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites	Phase 3
Completed	`NCT03563521` - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed	`NCT02990117` - ICS Treatment Compliance of Asthma Patients
Recruiting	`NCT04898283` - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.	Phase 3
Recruiting	`NCT03455959` - Lung-Resident Memory Th2 Cells in Asthma	N/A
Not yet recruiting	`NCT05352126` - Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.	N/A
Completed	`NCT01104012` - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis	N/A
Not yet recruiting	`NCT06027073` - Biologics and Sublingual Immunotherapy	Phase 4
Recruiting	`NCT05720325` - Dupilumab Effects Against Aeroallergen Challenge	Phase 2
Completed	`NCT03112577` - Study of REGN3500 and Dupilumab in Patients With Asthma	Phase 1
Recruiting	`NCT04891237` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen	Phase 3
Terminated	`NCT02953106` - Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis	Phase 4
Completed	`NCT06063044` - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed	`NCT03705325` - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer	N/A
Recruiting	`NCT05478824` - IL13 Signaling in Allergic Asthma
Suspended	`NCT04109807` - Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)	N/A
Withdrawn	`NCT04035109` - Anakinra as a Rescue Treatment for Allergic Inflammation	Phase 1/Phase 2
Recruiting	`NCT03983603` - Plant Stanol Esters and Preventing Asthma Symptoms	N/A
Not yet recruiting	`NCT05740748` - Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma	Phase 2